This page shows the latest gout news and features for those working in and with pharma, biotech and healthcare.
Ironwood claims FDA OK for former AZ gout drug. Duzallo will be launched in the US before the end of this year. ... The US FDA has approved Ironwood Pharma's combination gout therapy Duzallo, but with a warning that it can cause serious kidney failure.
AstraZeneca has sold a raft of older or non-core products over the past two years, including a $230m deal with Grünenthal for gout drug Zurampic.
A good example of this is a recent crowdsourcing campaign designed to generate patient insight to inform gout education. “ ... The gout crowdsourcing project demonstrated how patients not only valued their interaction with pharma, but that they also
In January it bought Crealta in a deal valued at $510m that brought in Krystexxa (pegloticase), an FDA-approved drug for chronic refractory gout.
AZ transferred EU and Latin America rights for its recently approved gout drug Zurampic to Gruenenthal in a deal valued at £230m, and sold its late-stage psoriasis candidate brodalumab to
AstraZeneca (AZ) has continued to refine its portfolio with the sale of European and Latin American rights to gout drug Zurampic. ... The deal is valued at $230m plus milestones and royalties, and also includes rights to a follow-up product, which
More from news
Approximately 9 fully matching, plus 42 partially matching documents found.
We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both
230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3 ready.
Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.
Zurampic, a Selective Uric Acid Reabsorption Inhibitor (SURI), works selectively to complement xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricaemia associated with uncontrolled gout, and was approved by the EMA ... licence. 270.
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 450. AstraZeneca (UK). Ironwood (US). US license and
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
THE OTHER SIDE OF … GOUT. “ I thought that prolonged treatment would control the symptoms and enable me to live a near to normal life”. ... She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise.
Patient Perspective: Gout. What is it like to live with gout? ... Listen to a first-hand account of the symptoms of gout, and how Graham manages his condition.
THE OTHER SIDE OF … GOUT. “ I thought that prolonged treatment would control the symptoms and enable me to live a near to normal life”. ... She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise.
THE OTHER SIDE OF … GOUT. “
THE OTHER SIDE OF … GOUT. “
More from PMHub
Approximately 3 fully matching, plus 4 partially matching documents found.
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...